JP2023509766A5 - - Google Patents
Info
- Publication number
- JP2023509766A5 JP2023509766A5 JP2022541951A JP2022541951A JP2023509766A5 JP 2023509766 A5 JP2023509766 A5 JP 2023509766A5 JP 2022541951 A JP2022541951 A JP 2022541951A JP 2022541951 A JP2022541951 A JP 2022541951A JP 2023509766 A5 JP2023509766 A5 JP 2023509766A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- expression construct
- immune
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958563P | 2020-01-08 | 2020-01-08 | |
| US62/958,563 | 2020-01-08 | ||
| PCT/US2021/012510 WO2021142127A1 (en) | 2020-01-08 | 2021-01-07 | A method of engineering natural killer cells to target cd70-positive tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509766A JP2023509766A (ja) | 2023-03-09 |
| JP2023509766A5 true JP2023509766A5 (https=) | 2023-12-27 |
| JP7690211B2 JP7690211B2 (ja) | 2025-06-10 |
Family
ID=76788268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541951A Active JP7690211B2 (ja) | 2020-01-08 | 2021-01-07 | Ｃｄ７０陽性腫瘍を標的化するようにナチュラルキラー細胞を操作する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230060351A1 (https=) |
| EP (1) | EP4087618A4 (https=) |
| JP (1) | JP7690211B2 (https=) |
| KR (1) | KR20220125805A (https=) |
| CN (1) | CN115243728A (https=) |
| AU (1) | AU2021205249A1 (https=) |
| BR (1) | BR112022013445A2 (https=) |
| CA (1) | CA3166832A1 (https=) |
| MX (1) | MX2022008485A (https=) |
| TW (1) | TW202135840A (https=) |
| WO (1) | WO2021142127A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024539129A (ja) * | 2021-10-21 | 2024-10-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増強された代謝適合性を有する治療用免疫細胞の製造方法およびその組成物 |
| WO2023100153A1 (en) * | 2021-12-03 | 2023-06-08 | Crispr Therapeutics Ag | Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy |
| KR20250004736A (ko) * | 2022-04-07 | 2025-01-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조작된 자연 살해 세포의 활성화 및 증대 및 항체와의 조합을 위한 방법 |
| WO2024251290A1 (en) * | 2023-06-09 | 2024-12-12 | Suzhou Cure Genetics Biosciences Co., Limited | Engineered immune cells and uses thereof |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686347B1 (en) | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| EP3230310B1 (en) | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
| AU2017237543B2 (en) * | 2016-03-23 | 2020-02-06 | Institut Pasteur Korea | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same |
| BR112019002035A2 (pt) * | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CN112020518A (zh) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| KR20210005240A (ko) | 2018-05-03 | 2021-01-13 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포 |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| CN109880802B (zh) | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
-
2021
- 2021-01-07 CA CA3166832A patent/CA3166832A1/en active Pending
- 2021-01-07 CN CN202180019200.XA patent/CN115243728A/zh active Pending
- 2021-01-07 AU AU2021205249A patent/AU2021205249A1/en active Pending
- 2021-01-07 MX MX2022008485A patent/MX2022008485A/es unknown
- 2021-01-07 WO PCT/US2021/012510 patent/WO2021142127A1/en not_active Ceased
- 2021-01-07 US US17/758,094 patent/US20230060351A1/en active Pending
- 2021-01-07 KR KR1020227027290A patent/KR20220125805A/ko active Pending
- 2021-01-07 BR BR112022013445A patent/BR112022013445A2/pt unknown
- 2021-01-07 JP JP2022541951A patent/JP7690211B2/ja active Active
- 2021-01-07 EP EP21738525.1A patent/EP4087618A4/en active Pending
- 2021-01-08 TW TW110100801A patent/TW202135840A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509766A5 (https=) | ||
| US11679132B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP7264954B2 (ja) | Ｈｅｒ２を標的とするキメラ抗原受容体 | |
| JP7300763B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP2022051744A (ja) | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 | |
| CN109385403B (zh) | 靶向gpc3的car nk细胞 | |
| EP3995512A1 (en) | Anti cd30 chimeric antigen receptor and its use | |
| JP2022548902A5 (https=) | ||
| JP2024519515A5 (https=) | ||
| BR112016023500B1 (pt) | Ácido nucleico que codifica um receptor quimérico, método para a preparação de uma célula hospedeira e usos do mesmo | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| CN108276493A (zh) | 一种新型嵌合抗原受体及其应用 | |
| JP6990244B2 (ja) | ヒトｃｄ１２３を標的とするキメラ受容体リガンド及びその応用 | |
| CN110564695A (zh) | 靶向前列腺癌的增强型car-t细胞及其制备方法和药物 | |
| JP2024527559A5 (https=) | ||
| JP2024525609A5 (https=) | ||
| KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
| JP2023548467A5 (https=) | ||
| CN119546327A (zh) | 多部分受体和信号传导复合物 | |
| KR20230066007A (ko) | 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도 | |
| CN111479918A (zh) | 细胞 | |
| JP2024525492A5 (https=) | ||
| WO2021057906A1 (zh) | 表达il-15的免疫效应细胞 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities |